By Julie Grisham – Memorial Sloan Kettering Cancer Center –
When it comes to giving immunotherapy to people with the most common form of lymphoma, the time of day may make a difference, according to new research from Memorial Sloan Kettering Cancer Center (MSK).
People who receive chimeric antigen receptor (CAR) T cell therapy in the morning may be more likely to have a good response than those who receive it later in the day, the international study finds. Although the research is preliminary, it suggests giving CAR T cell therapy based on the body’s circadian rhythms may be a way to further improve outcomes for some patients.
